Revolo Biotherapeutics has entered into a partnership with Northway Biotech, a global end-to-end biopharmaceutical contract development and manufacturing organization (CDMO), to manufacture its binding immuno-regulatory protein, ‘1805.   Northway will provide the full scope of its services ranging from cell line development to batch production of ‘1805 active pharmaceutical ingredients (API) and drug product, following current good manufacturing practices (cGMP), with quality assurance and regul...